Evidence map›Paper›PMID 41495838›Full record

ArticleBiology direct2026

A novel synergistic action of phage vB_PaeP_GZMU_A1002 with allicin against carbapenem-resistant Pseudomonas aeruginosa.

Yuan Fu, Jiayi Liu, Yinglin Yin, Kailin Yuan, Ziru Zhou, Lei Xu, Sifang Dou, Baoqi Cai, Zhihuang He, Wanyu Wang and 2 more

Abstract read
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuan Fu *GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Jiayi Liu *GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Yinglin Yin *GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Kailin YuanGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Ziru ZhouGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Lei XuGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Sifang DouGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Baoqi CaiGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Zhihuang HeGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Wanyu WangGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
Qiang XiaoPulmonary and Critical Care Medicine, Zhujiang Hospital of Southern Medical University, 253 Gongye Road, Haizhu District, Guangzhou, 510280, China.
Ping ChenGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China. chenping_cas@163.com.

Funding

the grant of State Key Laboratory of Respiratory Disease SKLRD-Z-202616the plan on enhancing scientific research in GMU 2024SRP037
6 · The paper itself

Abstract

The increasing problem of bacterial resistance to antibiotics necessitates the exploration of innovative antimicrobial strategies. Phage therapy is a promising solution; however, naturally occurring phages targeting resistant pathogens remain limited. This study aimed to isolate and identify phages that lyse carbapenem-resistant Pseudomonas aeruginosa (CRPA) from sewage and investigate the synergistic antimicrobial effects of phage therapy combined with allicin. A novel phage, vB_PaeP_GZMU_A1002, was successfully isolated and characterized, revealing a double-stranded DNA genome of 63,770 bp with no virulence or resistance genes, indicating its safety for application. This phage demonstrated good stability across various temperatures and pH levels, effectively inhibited the CRPA growth within 12 h, and achieved a biofilm clearance rate of about 50%. Notably, the combination of phage and allicin significantly enhanced antimicrobial efficacy, reducing effective concentrations of both agents. The synergistic action was likely due to increased damage to bacterial cell membranes and reduced cell surface hydrophobicity. This research highlights the potential of phage therapy, particularly when combined with natural compounds like allicin, as a viable approach to combat antibiotic-resistant infections.

Indexed as

Anti-Bacterial AgentsPhage TherapyPseudomonas aeruginosaPseudomonas PhagesSulfinic AcidsCarbapenemsDisulfidesDrug Resistance, BacterialallicinAnti-Bacterial AgentsCarbapenemsDisulfidesSulfinic AcidsAllicinCarbapenem-resistanceLytic bacteriophagePhage therapyPseudomonas aeruginosaSynergistic antimicrobial effect

Identifiers

PMID41495838
PMCPMC12870095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.